GL-0719 / Gliknik - LARVOL DELTA

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Gliknik Inc. | Trial completion date: Jan 2026 ➔ Jun 2026 | Trial primary completion date: Jan 2026 ➔ Jun 2026

Biomarker • First-in-human • Trial completion date • Trial primary completion date • Autoimmune Hemolytic Anemia • Complement-mediated Rare Disorders • Hematological Disorders

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Gliknik Inc. | Trial completion date: Jul 2025 ➔ Jan 2026 | Trial primary completion date: Jul 2025 ➔ Jan 2026

Biomarker • Trial completion date • Trial primary completion date • Autoimmune Hemolytic Anemia • Complement-mediated Rare Disorders • Hematological Disorders

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: Gliknik Inc. | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Biomarker • Trial completion date • Trial primary completion date • Autoimmune Hemolytic Anemia • Complement-mediated Rare Disorders • Hematological Disorders

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: Gliknik Inc. | Trial completion date: Oct 2023 ➔ Jul 2024 | Trial primary completion date: Oct 2023 ➔ Jul 2024

Biomarker • Trial completion date • Trial primary completion date • Autoimmune Hemolytic Anemia • Complement-mediated Rare Disorders • Hematological Disorders

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Gliknik Inc. | N=36 ➔ 52 | Trial completion date: Dec 2022 ➔ Oct 2023 | Trial primary completion date: Dec 2022 ➔ Oct 2023

Enrollment change • Trial completion date • Trial primary completion date

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Gliknik Inc.

New P1 trial